Comparison of effect on inflammation and Oxidative stress with Vildagliptin , Nateglinide versus Glimepiride

Comparison of effect on inflammation and Oxidative stress with Vildagliptin , Nateglinide versus Glimepiride - and Oxidative stress(VIOS) study-

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009947

Enrollment

Registered

2013-03-01

Start date

2013-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus

Interventions

Glimepiride 1mg/day Vildagliptin 100mg/day Nateglinide 270mg/day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes treated by diet and exercise, or arufa-GI. 1)arufa-GI treatment for at least 1 month was not changed dosage. 2)HbA1c 7.0-8.0%(NGSP) 3)age>=20

Exclusion criteria

Exclusion criteria: 1)type 1 diabetes, 2)past history including severe ketosis, diabetic coma or pre-coma wihtin 6 monthes prior to this trial, 3)severe infection, perioperative period, severe trauma, 4) hepatic dysfunction, 5)renal dysfunction, 6)heart failure, 7)oral mediacation except arufa-GI or insulin treatment, 8)steroid treatment, 9)BMI>=28, 10)unstable plasma glucose control(HbA1c>=0.5%/month), 11)pregnant, intention of becoming pregnant, 12)history of anaphylaxis of DPP-4 inhibitor and insulin secretion related drugs, 13)Any other condition which the attending physician feels would interfere with the trail participation

Design outcomes

Primary

Measure	Time frame
surrogate marker(inflammation and oxidative stress) after 3 month of treatment	—

Secondary

Measure	Time frame
glycemic control and lipid metabolism, functon of their liver and kidney, sefety evaluation after 3 month of treatment	—

Countries

Japan

Contacts

Public ContactRyo kodera

Okayama University Hospital Center for Innovative Clinical Medicine

kodera@cc.okayama-u.ac.jp086-235-6510

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026